Cladribine

Drug Profile

Cladribine

Alternative Names: 2-CdA; 2-Chloro-2-deoxyadenosine; 2-Chlorodeoxyadenosine; 2CDA; Chlorodeoxyadenosine; Intocel; Leustat; Leustatin; Leustatine; Movectro; Mylinax; N-l-Leucyl-doxorubicin; RWJ 26251

Latest Information Update: 10 May 2017

Price : $50

At a glance

  • Originator Scripps Clinic
  • Developer EMD Serono; Janssen-Cilag; Merck Serono; Orphan Australia
  • Class Antineoplastics; Deoxyadenosines; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Immunosuppressants; Purinergic P1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis; Leukaemia; Lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Hairy cell leukaemia; Leukaemia; Lymphoma; Multiple sclerosis
  • No development reported Psoriasis; Transplant rejection

Most Recent Events

  • 28 Apr 2017 Efficacy data from the retrospective subgroup analysis of phase III CLARITY trial in Multiple sclerosis presented at the the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 16 Sep 2016 New efficacy data from the phase III ORACLE-MS trial in Multiple sclerosis were presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
  • 16 Sep 2016 New pooled efficacy data from the phase III CLARITY and CLARITY- EXTENSION trial in Multiple sclerosis were presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top